2025年AACR信达生物展示多种新型分子的临床前数据，包括双特异性抗体、三特异性抗体和双特异性ADC-动脉网

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs

CISION 等信源发布 2025-04-28 08:00



可切换为仅中文







SAN FRANCISCO

旧金山

and SUZHOU,

和苏州，

China

中国

，

April 27, 2025

2025年4月27日

/PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies, tri-specific antibodies as well as bispecific antibody-drug-conjugates (ADCs) from its oncology pipeline will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

/PRNewswire/ -- 信达生物制药集团（“信达生物”）（港交所代码：01801），一家致力于开发、生产和商业化高质量药物，用于治疗肿瘤、心血管及代谢疾病、自身免疫疾病、眼科疾病及其他重大疾病的国际一流生物制药公司，宣布其肿瘤领域产品管线中的多种新型双特异性抗体、三特异性抗体以及双特异性抗体药物偶联物（ADC）的临床前数据将在2025年美国癌症研究协会（AACR）年会上展示。

The AACR meeting will take place .

AACR会议将举行。

April 25-30, 2025

2025年4月25日至30日

, in

，在

Chicago, Illinois

伊利诺伊州芝加哥市

。

Dr. Kaijie He, Cancer Biology and ADC Vice President of Innovent

和记黄埔医药副总裁、癌症生物学和ADC负责人何凯杰博士

, stated: 'With continuous advancement of Innovent Academy's integrated technology platforms, our global R&D capabilities have reached new heights, further strengthening our competitive position in the international biopharmaceutical landscape. This progress has accelerated our ability to design and develop innovative therapeutic candidates with significant global impact.

，表示：“随着信达学院一体化技术平台的持续进步，我们的全球研发能力达到了新的高度，进一步巩固了我们在国际生物制药领域的竞争地位。这一进展加快了我们设计和开发具有全球重大影响的创新治疗候选药物的能力。

We are proud to showcase a batch of preclinical research findings at this year's AACR Annual Meeting, including multiple globally first-in-class bispecific antibodies, multi-specific antibodies, and antibody-drug conjugates (ADCs). These scientific advancements highlight our expanding research expertise and underscore our unwavering dedication to creating life-changing treatments for patients across the globe.

我们很自豪在今年的AACR年会上展示了一批临床前研究成果，包括多个全球首创的双特异性抗体、多特异性抗体以及抗体药物偶联物（ADC）。这些科学进展彰显了我们不断拓展的研究实力，并凸显了我们为全球患者创造改变生命疗法的坚定承诺。

Moving forward, we remain deeply committed to scientific innovation—advancing target selection precision and pioneering unexplored biological mechanisms—to deliver breakthrough solutions for difficult-to-treat diseases and ensure more patients worldwide can access the benefits of cutting-edge therapeutic technologies.

展望未来，我们将继续坚定致力于科学创新——提升靶点选择的精准性并开创未被探索的生物学机制——为难以治疗的疾病提供突破性解决方案，确保全球更多患者能够受益于前沿治疗技术。

' .

Research highlights as below:

研究亮点如下：

Late-Breaking Research: Immunology 2

最新突破研究：免疫学 2

Topic:

主题：

Preclinical data of IAR037, a novel CD40/PD-L1 bispecific antibody for the treatment of advanced solid tumors resistant to immune checkpoint inhibitors

IAR037是一种新型的CD40/PD-L1双特异性抗体，用于治疗对免疫检查点抑制剂耐药的晚期实体瘤的临床前数据

Abstract Number:

摘要编号：

LB139

Presentation Form:

表现形式：

Poster

海报

Presentation Time:

演示时间：

Monday April 28, 2025

2025年4月28日，星期一

，

9:00 AM - 12:00 PM

上午9:00 - 上午12:00

Location:

位置：

Poster Section 52

海报部分 52

IAR037 is a novel CD40/PD-L1 bispecific antibody, which simultaneously activates CD40 and blocks PD-1/L1, demonstrating potent anti-tumor efficacy in PD-1-resistant syngeneic mouse models and synergy with PD-1/IL-2

IAR037是一种新型的CD40/PD-L1双特异性抗体，能够同时激活CD40并阻断PD-1/L1，在PD-1耐药的同源小鼠模型中显示出强大的抗肿瘤效力，并与PD-1/IL-2产生协同作用。

α-bias

α-偏差

fusion protein IBI363. Preclinical studies show tumor-specific immune activation with minimal systemic effects and a favorable safety profile in cynomolgus monkeys.

融合蛋白IBI363。临床前研究表明，在食蟹猴中具有肿瘤特异性免疫激活作用，全身性影响极小，并且安全性良好。

IAR037 presents a novel therapeutic approach for ICI-resistant advanced solid tumors and the IND-enabling study of IAR037 is ongoing.

IAR037 提供了一种针对 ICI 抗性晚期实体瘤的新型治疗方法，目前 IAR037 的 IND 前研究正在进行中。

Late-Breaking Research: Clinical Research 1

晚期突破性研究：临床研究 1

Topic:

主题：

Preclinical characterization of IBI3010, a FRα targeting biparatopic antibody-drug conjugate (ADC), for the treatment of FRα expressing tumors

IBI3010的临床前特性研究，一种靶向FRα的双表位抗体药物偶联物（ADC），用于治疗表达FRα的肿瘤

Abstract Number:

摘要编号：

LB222

Presentation Form:

表现形式：

Poster

海报

Presentation Time:

演示时间：

Monday April 28, 2025

2025年4月28日，星期一

，

2:00 PM - 5:00 PM

下午2:00 - 下午5:00

Location:

位置：

Poster Section 53

海报部分 53

IBI3010 is a FRα targeting biparatopic ADC with novel topoisomerase I inhibitor NT1 (DAR8). The biparatopic design enhances tumor binding/internalization.

IBI3010是一种靶向FRα的双表位ADC，具有新型拓扑异构酶I抑制剂NT1（DAR8）。双表位设计增强了肿瘤结合/内化。

IBI3010 shows superior cytotoxicity and bystander effect versus mirvetuximab soravtansine (IMGN853) in vitro. IBI3010 demonstrated superior antitumor activity to IMGN853 in FRα-expressing CDX models, particularly in low-FRα expression models. GLP tox studies in cynomolgus monkeys established 60 mg/kg as HNSTD with full tolerability..

IBI3010在体外显示出比米妥昔单抗索拉坦辛（IMGN853）更优的细胞毒性和旁观者效应。在表达FRα的CDX模型中，IBI3010表现出比IMGN853更强的抗肿瘤活性，尤其是在低FRα表达模型中。在食蟹猴中的GLP毒性研究确定了60 mg/kg为HNSTD，且具有完全的耐受性。

These data support the clinical development of IBI3010 to evaluate its potential as an ADC therapeutic for FRα-expressing solid tumors.

这些数据支持 IBI3010 的临床开发，以评估其作为 FRα 表达实体瘤的 ADC 疗法的潜力。

Poster Session:

海报会议：

Experimental and Molecular Therapeutics - Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies

实验性和分子治疗学 - 癌症的生化调节剂/分化治疗策略

Topic:

主题：

IBI3014, a TROP2xPD-L1 bi-specific ADC integrating ADC killing with checkpoint blockade within one molecule, exhibits promising efficacy and safety in preclinical models

IBI3014是一种结合ADC杀伤与检查点阻断于一体的TROP2xPD-L1双特异性ADC，在临床前模型中展现出良好的疗效和安全性。

Abstract Number:

摘要编号：

344

Presentation Form:

表现形式：

Poster

海报

Presentation Time:

展示时间：

Sunday April 27, 2025

2025年4月27日，星期日

，

2:00 PM - 5:00 PM

下午2:00 - 下午5:00

Location:

位置：

Poster Section 16

海报部分16

Poster Board Number:

海报板编号：

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 immune checkpoint blockade, enhancing immunogenic cell death and T cell infiltration.

IBI3014 是一种靶向 TROP2 和 PD-L1 的双特异性抗体偶联药物 (ADC)。其双重机制结合了 TROP2 介导的肿瘤杀伤与 PD-L1 免疫检查点阻断，增强免疫原性细胞死亡和 T 细胞浸润。

In CDX models with varying TROP2/PD-L1 expression, IBI3014 demonstrated superior cytotoxicity compared to benchmark ADCs, covering broader tumor types. It maintained stability in mice and monkeys, with a well-tolerated HNSTD of 50 mg/kg in monkeys.

在具有不同TROP2/PD-L1表达的CDX模型中，IBI3014显示出比基准ADC更优的细胞毒性，覆盖更广泛的肿瘤类型。它在小鼠和猴子体内保持稳定，在猴子中的HNSTD耐受性良好，剂量达50 mg/kg。

IBI3014's dual mechanism of action not only enhances therapeutic efficacy but also maintains a favorable safety profile, which provides a promising approach for cancer therapy.

IBI3014的双重作用机制不仅提高了治疗效果，还保持了良好的安全性，为癌症治疗提供了有前景的方法。

Poster Session:

海报展示环节：

Experimental and Molecular Therapeutics - Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies

实验性和分子治疗学 - 癌症的生化调节剂/分化治疗策略

Topic:

主题：

Trop2 and B7H4 bi-specific ADC with improved efficacy and safety for gynecologic cancers

Trop2和B7H4双特异性ADC在妇科癌症中显示出更高的疗效和安全性

Abstract Number:

摘要编号：

345

Presentation Form:

表现形式：

Poster

海报

Presentation Time:

演示时间：

Sunday April 27, 2025

2025年4月27日，星期日

，

2:00 PM - 5:00 PM

下午2:00 - 下午5:00

Location:

位置：

Poster Section 16

海报部分16

Poster Board Number:

海报板编号：

IBI3022, a bi-specific ADC targeting Trop2 and B7H4, aims to enhance tumor antigen expression and reduce off-tumor toxicity associated with Trop2 by incorporating a single-arm Trop2 antibody and a less toxic Topoi NT3 linker payload.

IBI3022是一种双特异性ADC，靶向Trop2和B7H4，旨在通过结合单臂Trop2抗体和较低毒性的Topoi NT3连接子载荷，增强肿瘤抗原表达并减少与Trop2相关的非肿瘤毒性。

In vitro studies demonstrate that IBI3022 exhibits superior cytotoxicity in HT29 cells overexpressing Trop2 and B7H4 compared to mono-specific ADC benchmarks targeting Trop2 or B7H4. In vivo, IBI3022 demonstrates enhanced tumor suppression compared to mono-specific ADC benchmarks in various tumor models with differing levels of Trop2 and B7H4 expression..

体外研究表明，与针对Trop2或B7H4的单特异性ADC基准相比，IBI3022在过表达Trop2和B7H4的HT29细胞中表现出更优的细胞毒性。在体内，IBI3022在不同Trop2和B7H4表达水平的各种肿瘤模型中，相较于单特异性ADC基准展现出更强的肿瘤抑制效果。

IBI3022 represents a promising bi-specific ADC for the treatment of gynecologic cancers, offering improved efficacy and safety profiles.

IBI3022 是一种有前景的双特异性抗体药物偶联物（ADC），用于治疗妇科癌症，具有更优的疗效和安全性。

Poster Session:

海报展示环节：

Experimental and Molecular Therapeutics - Therapeutic Approaches to Attack the Tumor Microenvironment

实验与分子治疗 - 攻击肿瘤微环境的治疗策略

Topic:

主题：

IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the breaks in immune response and strongly activating T and NK cells in the tumor microenvironment

IBI3026，一种首创的抗PD-1/IL-12融合蛋白，通过释放免疫反应的刹车并在肿瘤微环境中强烈激活T细胞和NK细胞，展现了成为一种新的免疫肿瘤疗法的潜力。

Abstract Number:

摘要编号：

3118

Presentation Form:

表现形式：

Poster

海报

Presentation Time:

演示时间：

Monday April 28, 2025

2025年4月28日，星期一

，

2:00 PM - 5:00 PM

下午2:00 - 下午5:00

Location:

位置：

Poster Section 24

海报部分 24

Poster Board Number:

海报板编号：

IBI3026 is a bispecific immune agonist targeting PD-1 and IL-12 receptor, designed to improve safety profile by reducing IL-12 activity while enabling tumor-targeted activation through PD-1+ T cell enrichment.

IBI3026是一种针对PD-1和IL-12受体的双特异性免疫激动剂，旨在通过降低IL-12活性来改善安全性，同时通过PD-1阳性T细胞富集实现肿瘤靶向激活。

IBI3026 demonstrated potent immune activation (STAT4/IFN-γ signaling) in pre-treated human PBMCs and achieved complete tumor suppression in multiple models (EMT6, CT26, A375, BxPC-3). In cynomolgus monkeys, the highest non-severely toxic dose (HNSTD) of IBI3026 is 150 mg/kg and the calculated therapeutic index is 63..

IBI3026在预处理的人外周血单核细胞中显示出强大的免疫激活作用（STAT4/IFN-γ信号传导），并在多个模型中实现了完全的肿瘤抑制（EMT6、CT26、A375、BxPC-3）。在食蟹猴中，IBI3026的最高非严重毒性剂量（HNSTD）为150 mg/kg，计算得到的治疗指数为63。

As a first-in-class candidate, IBI3026 combines PD-1 blockade with localized IL-12 activation, offering a promising strategy for tumors resistant to current immunotherapies.

作为同类首创候选药物，IBI3026 将 PD-1 阻断与局部 IL-12 激活相结合，为对当前免疫疗法产生耐药性的肿瘤提供了一种有前景的策略。

Poster Session:

海报展示环节：

Immunology - T Cell Engagers

免疫学 - T细胞结合剂

Topic:

主题：

A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy

一种2+1格式的MUC16靶向T细胞衔接器诱导MUC16依赖性T细胞活性并具有更强的抗肿瘤效力

Abstract Number:

摘要编号：

3510

Presentation Form:

表现形式：

Poster

海报

Presentation Time:

演示时间：

Monday April 28, 2025

2025年4月28日，星期一

，

2:00 PM - 5:00 PM

下午2:00 - 下午5:00

Location:

位置：

Poster Section 38

海报部分38

Poster Board Number:

海报板编号：

We developed a 2+1 format MUC16 TCE, with improved tumor cell binding affinity, enhanced tumor cell killing potency, and MUC16-dependent T cell binding and activation.

我们开发了一种2+1格式的MUC16 TCE，具有更高的肿瘤细胞结合亲和力、增强的肿瘤细胞杀伤效力，以及依赖MUC16的T细胞结合和激活能力。

Compared to the benchmark molecule, this MUC16 TCE showed limited T cell binding and activation without MUC16, minimizing off-target activity. This 2+1 format MUC16 TCE also showed a favorable pharmacokinetics profile in mice. Functionally, systemic administration of this MUC16 TCE showed superior anti-tumor efficacy, with undetectable toxicity, in xenograft models..

与基准分子相比，这种MUC16 TCE在没有MUC16的情况下显示出有限的T细胞结合和激活，最大限度地减少了脱靶活性。这种2+1形式的MUC16 TCE在小鼠中也显示出良好的药代动力学特性。在功能上，系统性给予该MUC16 TCE在异种移植模型中表现出卓越的抗肿瘤效果，且未检测到毒性。

This innovative TCE shows significant potential for treating MUC16-positive cancers, particularly chemotherapy-resistant ovarian cancer.

这种创新的TCE在治疗MUC16阳性癌症，特别是化疗耐药性卵巢癌方面，显示出显著的潜力。

Poster Session:

海报展示环节：

Experimental and Molecular Therapeutics - New and Emerging Cancer Drug Targets

实验与分子治疗学 - 新兴癌症药物靶点

Topic:

主题：

IBI3019, a first-in-class EGFR/CDH17/CD16A tri-specific antibody, demonstrated potent efficacy against CRC and an excellent safety profile in preclinical studies

IBI3019是一种首创的EGFR/CDH17/CD16A三特异性抗体，在临床前研究中显示出对结直肠癌的强大疗效和出色的安全性。

Abstract Number:

摘要编号：

4249

Presentation Form:

表现形式：

Poster

海报

Presentation Time:

演示时间：

Tuesday April 29, 2025

2025年4月29日，星期二

，

9:00 AM - 12:00 PM

上午9:00 - 上午12:00

Location:

位置：

Poster Section 17

海报部分17

Poster Board Number:

海报板编号：

IBI3019 is a novel tri-specific antibody targeting EGFR, CDH17, and CD16A for colorectal cancer treatment. It demonstrated strong tumor-specific EGFR inhibition by targeting the overexpressed CDH17 on tumors, while significantly reducing skin toxicities commonly associated with EGFR therapies.

IBI3019是一种新型的三特异性抗体，靶向EGFR、CDH17和CD16A，用于结直肠癌治疗。它通过靶向肿瘤上过度表达的CDH17，展示了强大的肿瘤特异性EGFR抑制作用，同时显著降低了与EGFR疗法常见的皮肤毒性。

Additionally, IBI3019 incorporates a high-affinity CD16A nanobody that showed better antibody-dependent cell cytotoxicity than those mediated by low-fucose Fc. Importantly, IBI3019 not only demonstrated superior

此外，IBI3019 还包含一种高亲和力的 CD16A 纳米抗体，该抗体表现出比低岩藻糖 Fc 介导的更好的抗体依赖性细胞毒性。重要的是，IBI3019 不仅展示了优越的性能。

in vitro

体外

and

和

in vivo

体内

anti-tumor efficacy to Cetuximab and Amivantamab but was also highly tolerable in cynomolgus monkeys with HNSTD at 150 mg/kg in a pilot tox study. These promising preclinical findings warrant further clinical exploration.

抗肿瘤功效与西妥昔单抗和阿米万他单抗相当，但在初步毒性研究中，以 150 mg/kg 的剂量对食蟹猴具有高度耐受性，且未观察到明显的毒性反应。这些令人鼓舞的临床前研究结果值得进一步开展临床探索。

Poster Session:

海报展示环节：

Immunology - Modulation of Tumor Microenvironment: Modulation of Lymphocyte Influx

免疫学 - 肿瘤微环境的调节：淋巴细胞流入的调节

Topic:

主题：

A PD1-IFNα fusion protein, with an attenuated IFNα fused to a clinically validated PD1 mAb, elicited PD1-dependent IFNα signaling and superior anti-tumor efficacy

一种PD1-IFNα融合蛋白，将减毒的IFNα与经过临床验证的PD1单克隆抗体结合，引发了PD1依赖性的IFNα信号传导，并展现出卓越的抗肿瘤效果。

Abstract Number:

摘要编号：

4881

Presentation Form:

表现形式：

Poster

海报

Presentation Time:

演示时间：

Tuesday April 29, 2025

2025年4月29日，星期二

，

9:00 AM - 12:00 PM

上午9:00 - 上午12:00

Location:

位置：

Poster Section 40

海报章节 40

Poster Board Number:

海报板编号：

We engineered a novel PD1-IFNα fusion protein that combines attenuated IFNα with Sintilimab, inducing potent PD1/PDL1 blockade while eliciting highly PD1-dependent IFNα signaling, selectively activating in PD1-high cells.

我们设计了一种新型的PD1-IFNα融合蛋白，将减毒的IFNα与信迪利单抗结合，诱导有效的PD1/PDL1阻断，同时引发高度依赖PD1的IFNα信号传导，在PD1高表达细胞中选择性激活。

Preclinical studies demonstrate superior anti-tumor efficacy compared to PD1 mAb alone in multiple mouse syngeneic tumor models, with undetectable toxicity and a favorable pharmacokinetics profile.

临床前研究在多个小鼠同基因肿瘤模型中显示出比单独使用PD1单抗更优的抗肿瘤效果，且未检测到毒性，药代动力学特性良好。

This bi-functional molecule potentially benefits patients with ICB-refractory cancers including pancreatic, ovarian, and MSS colorectal cancers.

这种双功能分子可能使对ICB耐药的癌症患者受益，包括胰腺癌、卵巢癌和MSS结直肠癌。

About Innovent

关于信达

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases.

信达生物成立于2011年，是一家领先的生物制药公司，其使命是为全球患者提供负担得起的高质量生物制药。该公司发现、开发、生产和商业化针对一些最难治疾病的创新药物。其开创性疗法治疗癌症、心血管和代谢、自身免疫和眼科疾病。

Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center..

信达生物已上市15款产品，有3个新药上市申请在审评中，4项资产处于III期或关键性临床试验，还有15款分子处于早期临床阶段。信达生物与30多家全球医药公司建立了合作关系，包括礼来、赛诺菲、Incyte、Adimab、LG化学和MD安德森癌症中心。

Guided by the motto, 'Start with Integrity, Succeed through Action,' Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit

信达秉承“诚信为本，行动致胜”的理念，坚持行业实践的最高标准，与各方携手合作，共同推动生物医药行业的发展，使一流的医药产品能够广泛普及。欲了解更多信息，请访问

www.innoventbio.com

, or follow Innovent on Facebook and LinkedIn.

，或者在 Facebook 和 LinkedIn 上关注信达。

Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s).

声明：（1）信达不建议使用任何未经批准的药物/适应症。

（

）

Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Ramucirumab（Cyramza）和Selpercatinib（Retsevmo）以及Pirtobrutinib（Jaypirca）由礼来公司开发。

Forward-looking statement

前瞻性声明

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words 'anticipate', 'believe', 'estimate', 'expect', 'intend' and similar expressions, as they relate to Innovent Biologics ('Innovent'), are intended to identify certain of such forward-looking statements.

本新闻稿可能包含某些前瞻性陈述，这些陈述因其性质而受到重大风险和不确定性的影响。与信达生物（“信达”）相关的诸如“预期”、“相信”、“估计”、“预计”、“意图”等词语及类似表达旨在识别某些此类前瞻性陈述。

The Company does not intend to update these forward-looking statements regularly..

公司不打算定期更新这些前瞻性声明。

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict.

这些前瞻性陈述是基于公司管理层在作出这些陈述时对未来事件的现有信念、假设、期望、估计、预测和理解。这些陈述并非对未来发展的保证，并受风险、不确定性和其他因素的影响，其中一些因素超出公司的控制范围且难以预测。

Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions..

因此，由于我们业务、公司竞争环境以及政治、经济、法律和社会条件的未来变化或发展，实际结果可能与前瞻性陈述中包含的信息存在重大差异。

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

公司、董事及公司员工假定：(a) 没有义务更正或更新本网站中包含的前瞻性陈述；以及 (b) 如果任何前瞻性陈述未能实现或结果不正确，概不承担责任。

SOURCE Innovent Biologics

来源：信达生物

WANT YOUR COMPANY'S NEWS

希望了解贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers